Boomray Pharmaceuticals Co., Ltd.
蘇州博銳創合醫藥有限公司
Licensing announcements since 2025
| Date | Counterparty | Asset / platform | Upfront | Near-term | Potential total | Stage at announcement |
|---|---|---|---|---|---|---|
| 2026-09-22 | Novartis Pharma AG | Radioligand therapy asset | Not disclosed | Not disclosed | ≤ USD 900,000,000 | Preclinical |